Retrophin, Inc. (RTRX) Stake Decreased by Wells Fargo & Company MN
Wells Fargo & Company MN trimmed its position in shares of Retrophin, Inc. (NASDAQ:RTRX) by 22.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,511 shares of the biopharmaceutical company’s stock after selling 11,274 shares during the quarter. Wells Fargo & Company MN owned 0.10% of Retrophin worth $767,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC boosted its position in shares of Retrophin by 1.8% during the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 146 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Retrophin by 4.3% during the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 355 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Retrophin during the second quarter worth $246,000. American International Group Inc. boosted its position in shares of Retrophin by 7.1% during the first quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 1,475 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in Retrophin by 67.5% in the 2nd quarter. Principal Financial Group Inc. now owns 21,334 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 8,596 shares in the last quarter.
In related news, COO Neil F. Mcfarlane sold 1,378 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the sale, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at approximately $306,495. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.41% of the company’s stock.
Several equities research analysts recently commented on the stock. ValuEngine raised shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. BidaskClub raised shares of Retrophin from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a research report on Friday, October 6th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Retrophin currently has an average rating of “Buy” and a consensus price target of $36.00.
Shares of Retrophin, Inc. (RTRX) opened at $25.23 on Wednesday. Retrophin, Inc. has a 52-week low of $15.55 and a 52-week high of $26.44. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.01 and a quick ratio of 3.96.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). The company had revenue of $38.80 million during the quarter, compared to the consensus estimate of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The company’s revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.07 earnings per share. research analysts forecast that Retrophin, Inc. will post -1.02 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Retrophin, Inc. (RTRX) Stake Decreased by Wells Fargo & Company MN” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/08/retrophin-inc-rtrx-stake-decreased-by-wells-fargo-company-mn.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.